INTRODUCTION
A perceived lack of transparency, including under-reporting of results, undermines the confidence of researchers, healthcare professionals and patients in conclusions drawn from clinical trials. [1] All clinical trial sponsors, be they biopharmaceutical companies or nonindustry bodies, such as government agencies, universities and research charities, have ethical obligations to register trials before they start and to report their results in a timely fashion after they finish. [2, 3] In the USA, EU and elsewhere, it is required that certain types of clinical trial are registered and their results posted on dedicated registries (e.g. EudraCT, the EU electronic Register of Post-Authorisation Studies and ClinicalTrials.gov) (Supplementary material, table S1). [4] [5] [6] [7] [8] [9] [10] [11] Other bodies, such as the World Health Organization (WHO) and the International Committee of Medical Journal Editors (ICMJE), have issued transparency standards and recommendations, [2, [12] [13] [14] and some biopharmaceutical companies have websites dedicated to their own trial results. [15, 16] This makes the clinical trial data transparency environment highly complex and diverse.
Within the biopharmaceutical industry, which is responsible for approximately half of all clinical trials, [17, 18] In the present study, we aimed to evaluate the extent to which EFPIA/PhRMA members and non-members among the leading biopharmaceutical companies have committed to the responsible disclosure of clinical trial results. We also evaluated the reporting of results from clinical trials sponsored by biopharmaceutical companies compared with those from other sponsors.
METHODS

Commitment to disclosure of clinical trial data by EFPIA/PhRMA member companies
The global public websites of each EFPIA and/or PhRMA ('EFPIA/PhRMA') member and non-member company in the top 50 companies by 2015 worldwide prescription sales ('top 50 companies') [20] were searched by one researcher (JP) for direct links to pages containing: (i) a general statement of commitment to disclosing clinical trial data; (ii) a general statement of commitment to disclosing clinical trial data according to EFPIA/PhRMA joint principles; and (iii) specific statements detailing commitments to upholding one or more of the five individual EFPIA/PhRMA joint principles for responsible disclosure of clinical trial data. If no direct links to such pages were found, the free-text search function of each website was used to search for statements relating to clinical trial data disclosure and implementation of the EFPIA/PhRMA disclosure principles using one or more the key words "EFPIA", "PhRMA", "data sharing", "clinical trials" and "transparency". EFPIA/PhRMA membership was determined from the websites of these two organisations (www.efpia.eu/about-us/membership and http://www.phrma.org/about/members).
Ease of access to relevant information was assessed; good access was rated as requiring either no more than four clicks from the homepage of the company website, [21] or a clear, direct link, poor access was rated as either needing more than four clicks or requiring navigation to satellite websites (e.g. blogs).
Clinical trial results reporting
TrialsTracker is an independent, semi-automated, web-based tool that has been developed in an effort to incentivise sponsors of clinical trials to improve disclosure rates by highlighting the disclosure performance of individual sponsors (trials without results disclosed as a proportion of trials registered). [22] For clinical trial sponsors to be included in TrialsTracker, An analysis of disclosure rates was performed on subsets of the industry sponsors within TrialsTracker based on sales revenue (the top 50 companies) [20] and membership of EFPIA/PhRMA. An arbitrary disclosure rate threshold of 80% was applied to sponsor subgroups.
Exploratory analysis of results posted on websites other than ClinicalTrials.gov
In an exploratory analysis, clinical trial results from locations other than ClinicalTrials.gov or from linked publications in PubMed were sought for three studies that were blindly selected from four of the top 50 companies. ClinicalTrials.gov was searched by National Clinical Trial (NCT) identifier in order to establish the presence or absence of posted results and/or links to publications on PubMed. We made a separate search of PubMed, Google Scholar and Google using the NCT identifier, and a search of EudraCT and the relevant company's website based on NCT identifier and study title. 
Data analysis
Disclosure rates for all industry sponsors, the top 50 companies and EFPIA/PhRMA members in the top 50 companies were compared with those for non-industry sponsors.
Patient involvement
Patients were not directly involved in conducting this study, but patients' perspectives were sought during the development of the manuscript. 
RESULTS
Commitment
Clinical trial results reporting
Of 29 377 trials listed in TrialsTracker, 9511 (32%) were sponsored by 69 biopharmaceutical companies (a mean of 138 trials per company) and 19 866 (68%) were sponsored by 254 nonindustry institutions (a mean of 78 trials per institution) (figure 1). Of all undisclosed trials, 81%
were sponsored by non-industry institutions and 19% were sponsored by industry. The mean disclosure rate for all trials was 55%, with higher rates for industry (74%) than for non-industry sponsors (46%) (figure 2; Supplementary material, table S2).
The overall disclosure rate for all clinical trials substantially increased during 2007 and 2008, before declining thereafter. The maximum mean disclosure rate for all clinical trials was observed in 2008 (66%); for industry-and non-industry-sponsored trials, the maximum mean disclosure rates were in 2012 (83%) and 2009 (56%), respectively (figure 2). Disclosure rates for non-industry sponsors followed a trend similar to those for all sponsors, whereas disclosure rates for industry sponsors were maintained at approximately 80% until 2014 (figure 2).
There was high variability in disclosure rate between sponsor type (figure 3A). The highest disclosure rate achieved by a non-industry sponsor was 84%, whereas two biopharmaceutical industry sponsors achieved 100% disclosure. Of the top 50 companies, a mean of 76% of trials were disclosed by the 30 companies with data reported in TrialsTracker (all of which were pharmaceutical/biotechnology companies). The mean disclosure rate was 77% for EFPIA/PhRMA members (25 companies) and was 67% for non-members (5 companies) (figures 2 and 3B). An arbitrary disclosure rate threshold of 80% was reached by fewer than 1% of non-industry sponsors compared with 39% of industry sponsors. Of the 69 biopharmaceutical industry sponsors with results in TrialsTracker, the 80% threshold was met by 56% of EFPIA/PhRMA members in the top 50 companies, by 20% of EFPIA/PhRMA non-members in the top 50 companies, and by 31% of biopharmaceutical industry sponsors that were not in the top 50 companies (figure 3B).
DISCUSSION
This analysis of the disclosure environment of clinical trial sponsors began with a review of the publicly stated disclosure policies of the top 50 biopharmaceutical companies. Of these, 26 companies (52%; all of which were members of one or both of the two leading international industry bodies [EFPIA and PhRMA]) had disclosure policies available on their websites. Most EFPIA/PhRMA members (87%) communicated that they had a commitment to disclose clinical trial results and two-thirds (67%) specifically referred to the EFPIA/PhRMA joint principles; approximately half (53%) described those principles in detail.
To be useful, information on websites should be easy to find and have a logical flow. The 'threeclick rule' is no longer regarded as the benchmark for website utility, [21, 23] therefore four clicks were used to define information as having good access. Inherent in the principle of publicly committing to data disclosure should be that the statements have good accessibility.
The second phase of our collated disclosure information from a large number of trials and sponsors over a 10-year period using data from TrialsTracker. [22] The proportion of trials identified in the present study as sponsored by the biopharmaceutical industry (approximately one-third of all trials) was similar to that reported previously. [17, 26] Although the disclosure rate for industry-sponsored studies was similar to that previously observed using TrialsTracker and the EU Clinical Trials Register (EUCTR), [22, 27] this rate is lower than the rates reported for newly approved drugs in the USA and Europe, [28, 29] and either lower than or similar to rates of publication that have been reported by single sponsors. [24, 25] Similarly, for non-industry studies, the disclosure rate was similar to that previously seen with TrialsTracker, [22] and either lower than or similar to those reported for academic medical centres in the USA and the UK, but higher than for EUCTR. [18, 27, 30, 31] Our assessment of biopharmaceutical company disclosure policies showed results similar to those from a recent EFPIA/PhRMA survey in which 77% of the 44 EFPIA/PhRMA members confirmed that they state on a publicly available website that they adhere to the joint principles. [32] In a recent survey of the internal disclosure policies of 25 top biopharmaceutical companies, 96% reported that they had a policy committing to the sharing of summary results in academic articles or on a clinical trial registry. [33] However, in the present study, we found such commitments on the websites of only about half of the top 50 companies, suggesting that many companies are missing the opportunity to share their disclosure policies.
In contrast to the results for EFPIA/PhRMA members, but in line with those for non-member companies, a preliminary review of commitments to data transparency that was conducted for S3 ). The requirement for EFPIA/PhRMA members to commit publicly to data disclosure is reflected in clear differences between these companies and non-members/non-industry sponsors.
Because we used data from TrialsTracker, which searches on ClinicalTrials.gov using only NCT identifiers, we made an exploratory search of alternative sources of clinical trial data for 12 clinical trials sponsored by four of the top 50 biopharmaceutical companies. Some results that were missing from ClinicalTrials.gov were found on EudraCT and company websites, suggesting that TrialsTracker was underestimating the number of trials that had published results. As recommended by the ICMJE, the inclusion of the study, NCT and/or EudraCT numbers in the abstract of publications linked to clinical trials would help to improve assessments of the disclosure of clinical trial data. [7] Clinical trials require a high level of trust between the patient, the medical team and the trial sponsor. Central to the trust placed in the sponsor by the patient is that the results of the trial will be made publicly available. Many patients enrol in clinical trials not only in the hope of improving their own health, but also in the expectation that their participation will contribute to a better understanding of their condition and to the development of potential new treatments.
Participants must weigh these potential benefits against the risk of adverse reactions, which may be serious or severe and possibly life-threatening. For their involvement in clinical trials to have meaning to the participants, trial sponsors should release all results, both positive and negative.
Strengths and limitations
Our study was based on an evaluation of a large number of phase II-IV clinical trials from industry and non-industry sponsors over a 10-year period; however, several caveats should be considered when interpreting the results. First, it should be noted that the results obtained from
TrialsTracker are subject to error in the reporting rate. As per the methods outlined in a previous article, [22] ClinicalTrials.gov. Because publications were identified through automated searches of PubMed for NCT identifiers, identification and discoverability were limited to trials published with NCT identifiers included in the secondary source ID field of PubMed, title or abstract. [35, 36] Results disclosed elsewhere (e.g. institutional websites) or published without reference to the NCT identifier could lead to the understating of disclosure rates. Fourthly, our study looked only at the disclosure of registered studies but not all studies are registered; indeed, unregistered studies seem to be less likely than registered studies to be published. [37] Finally, our analysis of publicly available disclosure policies used key word searches that focused on disclosure, so it is possible that specific publication policies were missed. Nevertheless, our findings suggest that statements related to the disclosure of results are difficult to find in many cases.
The problem of incomplete and inconsistent clinical trial disclosure remains, despite public awareness campaigns and the introduction of various policies, legislation and fines. Companysponsored trials have been the focus of many of these activities because of their perceived commercial influence. [22] However, the present data demonstrate that results from trials sponsored by the biopharmaceutical industry are disclosed more often than those from nonindustry funded studies. The results of our analysis agree with those from two recent studies that reported that industry funders disclose the results from a higher proportion of their trials than do non-industry funders. [18, 27] These findings may reflect the considerable resources that commercial organizations have dedicated to clinical trial disclosure. They also suggest that the focus of future efforts to improve trial disclosure should shift towards the harmonisation of clinical trial data transparency principles to make them more easily implemented by organisations without the resources of pharma companies. This could be achieved by active discussion between, and endorsement by, all stakeholders, including clinical trial sponsors, regulatory bodies and other public bodies (e.g. WHO, ICMJE and EU Council), as well as those campaigning for increased transparency of clinical trial information. We believe that well-defined • sample proportion (p̂) =
• standard error (SE) = √((p̂× (1 − p̂ )) ×
• z-score = The null hypothesis (H0) was for no difference in the proportions of disclosed trials between industry and non-industry sponsors. 
